Learn about Bydureon BCise (extended-release exenatide), which is a prescription injection used for type 2 diabetes in certain adults and children.

Bydureon BCise is a prescription drug used to treat type 2 diabetes in adults and some children. Learn about the drug’s dosage, form, strength, and more.

WILMINGTON, Del., Jan. 10, 2018 /PRNewswire/ -- AstraZeneca today announced that BYDUREON ® BCise™ (exenatide extended-release) injectable suspension 2mg is now available in pharmacies across ...

Bydureon (Amylin and Alkermes), a once-weekly formulation of exenatide, has been made available for the treatment of type 2 diabetes. Skip to navigation Skip to main content. Menu Close.

Courtesy of AstraZeneca. Bydureon BCise, a glucagon-like peptide-1 (GLP-1) receptor agonist, is available in single-dose autoinjectors containing 2mg exenatide in 0.85mL vehicle in 4-count cartons.

First and Only Once-Weekly Type 2 Diabetes Medication Delivers Powerful Glycemic Control in a Single DoseINDIANAPOLIS, SAN DIEGO and WALTHAM, Mass., June 21, 2011 /PRNewswire/ -- Eli Lilly and ...

The market for drugs to treat diabetes — especially Type 2 diabetes — has shown quite a bit of activity lately. At the end of January, the Food and Drug Administration approved Bydureon ...

The FDA approved Amylin Pharmaceuticals' diabetes drug Bydureon after a prolonged regulatory process to address safety concerns.

BYDUREON Would Be First Once-Weekly Treatment for Adults with Type 2 DiabetesINDIANAPOLIS, SAN DIEGO and WALTHAM, Mass., April 15, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), together ...

According to Mark Schoenebaum, the analyst at ISI Group, Amylin will be allowed to conduct its heart rhythm study of the drug Bydureon using an IV formulation of its ...